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Abstract: Colorectal cancer is a major health burden, and a leading cause of cancer-related 
deaths in industrialized countries. The steady improvements in surgery and chemotherapy 
have improved survival, but the ability to identify high- and low-risk patients is still 
somewhat poor. Molecular biology has, over the years, given insight into basic principles 
of colorectal cancer initiation and development. These findings include aberrations 
increasing risk of tumor development, genetic changes associated with the stepwise 
progression of the disease, and errors predicting response to a specific treatment. Potential 
biomarkers in colorectal cancer are extensively studied, and how the molecular aberrations 
relate to clinical features. Yet, little of this knowledge has been possible to transfer into 
clinical practice. In this review, an overview of colorectal cancer genetics will be given, as 
well as how aberrations found in this tumor type are proposed as biomarkers for risk 
prediction, as diagnostic tools, for prognosis or prediction of treatment outcome. 
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1. Introduction 
Colorectal cancer (CRC) is a major health burden in the western world. The disease normally 
develops from a benign polyp through an adenoma with dysplasia into a carcinoma with metastatic 
potential. The high incidence combined with high mortality from the disease if diagnosed at a late 
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stage, signifies the need for better diagnostic, prognostic and predictive tools. The emergence of 
knowledge on the molecular level has gained insight in causes for initiation and progression of tumor 
development. This knowledge has also revealed the complexity and heterogeneity of the disease, 
explaining why few biomarkers are in routine clinical use.  
Cancers arise as a result of genetic and epigenetic alterations accumulating in a cell [1]. These 
changes lead to dysregulation of fine-tuned pathways, and thereby disturb the normal proliferation and 
growth of the cell. Predominantly, colorectal cancer arises sporadically, although a smaller subgroup 
arises either as a result of inherited mutations, or as a result of inflammatory bowel disease (IBD; 
Crohn’s disease or ulcerative colitis). 
Roughly, three molecular subtypes of colorectal carcinomas (CRC) are described based on 
molecular characteristics of the tumor; microsatellite instability (MSI), chromosomal instability (CIN), 
and CpG island methylator phenotype (CIMP). In addition, all of these three subgroups have mutations 
in protein coding genes, as well as impaired gene functions, and changes in expression of microRNAs 
(miRNA) that results in changes in gene expression.  
Patient response to treatment is diverse, even if their disease seems similar when evaluating 
clinicopathological parameters. There is increasing evidence that treatment response is dependent on 
the normal genetic background of the individual in addition to aberrations in the tumor itself. Mapping 
the genetic defects in a patient tumor is yet of limited clinical importance, as the prognostic and 
predictive value is scarce. However, a large body of information about genetic aberrations underlying 
CRC has revealed complex and heterogeneous mechanisms underlying the occurrence of disease. This 
information is of the essence for understanding the disease behavior and related clinical outcome, and 
especially for future improvements in treatment and survival for the patients. 
The current review article addresses some of the key concepts in CRC development, and outlines 
how genetic and epigenetic aberrations can be utilized as biomarkers for the disease in the future. 
2. Phenotypic Subgroups of CRC 
Chromosomal aberrations and aneuploidy are known as a hallmark of solid tumors. In colorectal 
cancers the large portion of the tumors display numerical chromosomal alterations, referred to as 
chromosomal instability (CIN) [2]. These CIN tumors have chromosomal composition which changes 
at a higher rate compared to normal cells, and recurrent gains and losses seem to affect chromosomes 
in a non-random manner [3]. The underlying cause(s) of CIN is to date not known, but alterations in 
mechanisms associated with chromosome segregation during mitosis are suggested [4,5]. The tumors 
in which mutations in microsatellites are demonstrated are referred to as microsatellite instabile  
(MSI) [6]. Tumors of the MSI phenotype have defects in the mismatch machinery, leaving errors 
introduced during replication unrepaired. Microsatellites are repetitive units, and therefore more prone 
to errors, and exist in both protein-coding and non-coding regions of the DNA. Deficient effect of 
mismatch repair genes has been found to cause this effect, either due to mutations in or as a result of 
hypermethylation of the promoter of these genes. Tumors harboring the latter of these aberrations have 
changes in the normal promoter methylation pattern. Methylation is chemical modification of DNA 
that leads to gene expression changes. This phenotype was discovered somewhat later than the CIN Int. J. Mol. Sci. 2011, 12 9428 
 
and MSI phenotypes, and named CpG island methylator phenotype (CIMP) [7,8]. As for the CIN 
phenotype, the underlying cause for CIMP is not revealed. 
Initially, the CIN and MSI phenotype was thought of as mutually exclusive, but later found to be 
partly overlapping. The CIMP phenotype is largely overlapping with the MSI phenotype, and to some 
extent with CIN tumors. There is a small subgroup of tumors in which none of the phenotypes are 
detected, referred to as triple negative [9]. 
3. Biomolecules 
The constant development and refinement of molecular techniques and knowledge about traits   
have increased our understanding of the human genome and its complexity in general, as well as  
cancer-specific aberrations. The total DNA content in a cell is referred to as the genome. The genes 
encoded by the genome are composed of both introns and exons, exons being the mRNA-encoding 
entities. The total content of mRNA in a cell at a given time point is referred to as the transcriptome. 
MicroRNAs (miRNA) are short RNA molecules that bind to complementary mRNA molecules, 
hindering the translation of the mRNA into a protein. In recent years both complete cancer genomes, 
transcriptomes, and exomes have been sequenced [10–12], DNA methylation profiles have been used 
to subgroup colorectal carcinomas [13], and even nucleic molecules such as microRNAs (miRNA) 
have been shown to play a role in cancer [14,15]. As non-protein-coding transcripts have been conserved 
throughout evolution, indicates that crucial functions exist for these molecules. For example, 
microRNAs (miRNAs) have been found to modulate several cellular processes [16]. The protein 
classes of RNA-binding proteins include essential regulators of miRNA biogenesis, turnover and 
activity. RNA-RNA and protein-RNA interactions are essential for post-transcriptional regulation in 
normal development and may be deregulated in disease. DNA, mRNA and miRNA are released and 
circulate in the blood [17]. Changes in the levels and types of circulating nucleic acids have been 
associated with tumor burden and malignant progression. Consequently, their potential role as markers 
of disease or risk for cancer is currently intensively investigated. 
Faster and cheaper sequencing technology has made comparison of tumor exomes from patients 
with the same tumor type possible, helping the identification of cancer-driving mutations [12]. Also, 
comparison of primary tumor and the associated distant metastasis has aided the search for genes, 
which is important for the metastatic process or the progression of disease [18]. 
4. Adenoma Carcinoma Sequence 
In colorectal cancer, adenomas are considered the most important precursor lesion for carcinomas, 
although a subgroup of hyperplastic polyps have also been shown to have malignant potential [19]. By 
the age of 70 years around 50% of the population has one or several adenomas presented in the colon. 
However, not all adenomas progress to carcinomas. The adenoma-carcinoma sequence suggests that 
specific mutations occur at specific stages, in order to transform the cell to a carcinoma with a 
metastatic potential. These mutations affect genes and pathways important for regulation of cell 
growth and differentiation.  
The WNT pathway increases the proliferation rate in a cell when active, and is known as an early 
event in the adenoma-carcinoma-sequence [20]. The APC gene is thought to be the initial event Int. J. Mol. Sci. 2011, 12 9429 
 
transforming a normal cell into an adenoma, and is found in ~80% of all colorectal carcinomas. If APC 
is mutated, the WNT signaling pathway is constantly on, even if WNT signal is absent, and the cell 
proliferates, Figure 1. Mutation in the oncogene KRAS is another aberration seen both frequently 
(~40%), and early in the transformation of normal cells. Mutations in the oncogene BRAF, yet another 
gene in the MAPK pathway, are seen early in malignant transformation. Both KRAS and BRAF 
mutations will increase the proliferation rate in the cell, comparable to mutations in APC. The TGFb 
pathway has been shown to be abrogated later in the development, transforming an intermediate 
adenoma to a late adenoma. Mutations in SMAD4, TGFBR2 or deletions at 18q are observed [21]. 
Mutations in the tumor suppressor gene TP53, or loss of 17p where TP53 is located, are observed in 
more than 50% of colorectal tumors, and as late events in CRC development. This high frequency of 
TP53 inactivity found in carcinomas, but not in adenomas, suggests TP53 to be pivotal for the 
malignant transformation of the cell. 
A subgroup of hyperplastic polyps, sessile serrated adenomas, were previously regarded as not 
giving increased risk of colorectal carcinoma development [19]. An equivalent to the adenoma-carcinoma 
sequence has been suggested for these adenomas [22], of which an activating mutation in the BRAF 
gene is regarded as the initiating event of the malignant transformation. Furthermore, methylation of 
promoter regions resulting in epigenetic silencing of a number of genes is observed in these lesions, 
the so-called CIMP phenotype. The MLH1 gene is one of the genes frequently shown to be methylated, 
and abrogation of the normal function of MLH1 will eventually cause MSI tumors. The observation 
that sessile serrated adenomas gives rise to CIMP and MSI tumors are supported by the fact that these 
polyps are most frequently found in the right colon [23,24]. 
Figure 1. Signaling pathways frequently found to be changed in colorectal cancer [25]. 
 
Genes found to be mutated in cancer cells have been defined as either proto-oncogenes or tumor 
suppressor genes. The proto-oncogenes are promoting cell growth, and when mutated the proliferation 
rate in the cell is high even in the absence of growth signals. In contrast, mutant tumor suppressor 
genes are deprived of their cell cycle regulatory function, resulting in cell proliferation even if severe Int. J. Mol. Sci. 2011, 12 9430 
 
damages are introduced in the cell–thus, the normal regulation and balance between apoptosis and 
proliferation is skewed towards an uncontrolled proliferative state with loss of cell death. However, 
several more hallmarks are needed for a cancer cell to sustain its growth, expand, invade and ultimately 
seed and soil its metastatic cells in distant organ sites.  
Sjoblom et al. [26] and Wood et al. [27] reported that around 70 genes on average are mutated in a 
colorectal tumor sample, of which ~10 are likely to drive tumorigenesis, based on sequencing of 
13,023 protein coding genes. Later, Timmermann et al. [12] performed exome sequencing (16,755 
RefSeq genes) of MSI and microsatellite stable (MSS) CRCs, and compared the mutation pattern in 
each tumor to normal colonic mucosa from the same patient. This highlighted specific mutation 
patterns in the two CRC subtypes, and 359 and 45 functionally significant mutations were reported in 
MSI and MSS tumors, respectively, which confirms MSI as the mutator phenotype. Furthermore, the 
BMPR1A gene, mutated in germline cells in juvenile polyposis, was found to be mutated in both MSI 
and MSS tumors, indicating that this gene might also have an important function in sporadic   
CRC development. 
5. Biomarkers 
The growing insight in molecular mechanisms of cancers has increased the expectations of these 
aberrations and compounds to be used as biomarkers. A plethora of molecules have been suggested as 
markers for risk, diagnosis, prognosis and treatment response, Table 1. But so far, mutations in the 
oncogene KRAS is the only biomarker in routine clinical use in CRC, validated to have information 
predicting response to treatment, [28].  
Table 1. Type of biomarkers, and examples of biomarkers in use/suggested for use in 
colorectal cancer. 
Type of Biomarker  Objective for use  Biological marker  References 
Risk stratification  Assess the likelihood that cancers 
will develop 
APC, AXIN2, BMPR1A, SMAD4, 
MUTYH, MSH2, MLH1, MSH6, PMS2, 
STK11, PTEN, EPCAM, 8q24, 15q13.3, 
SMAD7, LOC120376 
[29–40] 
Screening  Detect cancers in the 
asymptomatic population 
Stool tests, blood based tests  [41] 
Diagnosis  Definitively establish the presence 
of cancer 
Vimentin (ColoSure *), SEPT9 
(ColoVantage *), miR-17-3p, miR-92 
[42–44] 
Classification  Classify patients by disease subset  MSI, CIN, CIMP   
Prognosis  Predict the probable outcome of 
cancer regardless of therapy 
MSI, 18-gene signature (ColoPrint *), 
12-gene signature (OncoType DX *), 
GCC expression (Previstage *), miR-21 
[45–53] 
Prediction/treatment 
stratification 
Predict response to particular 
therapies and choose the drug that is 
mostly likely to yield a favorable 
response in a given patient 
EGFR, KRAS, BRAF, PIK3CA, PTEN, 
TP53, miR-140 
Panel (TP53, KRAS, CCDN1, MTHFR) 
[54–56] 
Abbreviations; MSI: microsatellite instability, CIN: Chromosomal instability, CIMP: CpG island methylator 
phenotype; * Details of biomarkers used are specified in Supplementary Table 1. Int. J. Mol. Sci. 2011, 12 9431 
 
5.1. Markers Aiding in Prediction of Risk 
Familial syndromes are estimated to cause 25% of colorectal cancer, but only around 5% of 
colorectal cancers are identified to have a known genetic defect [57]. The best described syndromes 
are Lynch syndrome (aka Hereditary Non-Polyposis Colorectal Cancer, HNPCC), developed on a 
background of an inherited germline defect DNA-mismatch repair systems leading to widespread MSI, 
and the Familial Adenomatous Polyposis (FAP) syndrome, caused by germline mutations in the APC 
gene. HNPCC is clinically associated with other cancers such as gastric and endometric cancer but no 
widespread development of colonic polyps despite cancer development at an early age (<50 years). 
FAP patients however, develop polyps in hundreds and thousands, necessitating total colectomy often 
at or before the age of 20 to avoid malignant transformation. Although most patients do not fall into 
one of these two hereditary categories, many patients may have family members with the disease, 
despite no clear cut genetic association found. However, to date, several genes are known to harbor 
mutations causing hereditary syndromes involving colorectal cancer [58–60].  
In addition to inherited mutations, a number of chromosomal locations and single nucleotide 
polymorphisms (SNPs) have been suggested as having increased risk for CRC development,   
but few have been validated in larger cohorts. However, in 8q24 [34–37], 15q13.3 [29,37,38],   
SMAD7 [32,37,39,40], and LOC120376 [33,37,39], SNPs have been validated, and each of them 
shown to be associated with increased risk of CRC development. Furthermore, if the SNP is located in 
a miRNA target site it might interfere binding, resulting in changes in gene and protein expression. 
More aberrations, especially those causing disease in a recessive manner, are predicted to be 
discovered in the future.  
5.2. Diagnostic Markers 
Early detection of colorectal cancer is pivotal for a good outcome of the disease. The fecal occult 
blood test (FOBT) is a non-invasive diagnostic test based on detection of blood in the feces. The test 
has shown low sensitivity and specificity, especially for early disease stages, as not all cancers bleed, 
and bleeding can be caused by other conditions than cancer. Whether the test reduces mortality is 
debated [61], although at least three large randomized controlled trials have demonstrated a reduction 
in cancer-specific mortality with the use of FOBT. A further drawback is the need for invasive   
follow up (usually by colonoscopy) for positive findings. Screening populations using colonoscopy or 
sigmoidoscopy is expensive and unpleasant for the individual, which reduces the compliance among 
patients. Further colonoscopy is associated with a small but relevant risk for adverse event (perforation 
during the procedure) which may indeed be life-threatening. “Virtual colonography” or CT colonography 
has been proposed as a non-invasive alternative, but introduces the risk of radiation exposure, and 
again, a number of follow up test will be needed to investigate positive findings. Consequently, the 
need for better and preferably less invasive tests are warranted. Testing for changes in methylation 
pattern in feces and blood samples have shown improvements in sensitivity and specificity compared 
to the FOBT test [61,62]. The commercially available test ColoSure
TM examines methylation in the 
Vimentin gene in feces samples, for early diagnosis of CRC [63,64]. Although its sensitivity (77%) and 
specificity (83%) is enhanced compared to FOBT, detection rates have not been assessed in a normal Int. J. Mol. Sci. 2011, 12 9432 
 
population and its clinical utility is therefore not established [42]. Panels of methylated genes have 
been recognized in feces samples, in which increased sensitivity and specificity of colorectal tumors 
are identified [65,66]. 
The presence of methylation of the Septin9 (SEPT9) gene has been shown to be highly correlated to 
occurrence of colorectal tumor cells. [67] Testing for methylation of SEPT9 in plasma has been 
commercialized as ColoVantage
TM.  
Using dysregulation of the expression of circulating miRNAs as markers for early diagnosis has 
gained more attention over the last years. In a study by Ng et al., elevated levels of miR-17-3p and 
miR-92 were reported to be statistically significant compared to the levels in healthy individuals, and 
also compared to gastric cancer and inflammatory bowel disease [44]. 
5.3. Prognostic Markers 
Even if meta-analyses have clearly shown a better prognosis of MSI cancers compared to CIN [68], 
clinical and histopathological data is still used as the main prognosticator and basis for treatment 
regime in CRC. The outcome of patients at disease stage II and III is however difficult to predict. 
Especially, for stage II cancers, defined on the basis of not finding metastases in lymph nodes, which 
could be erroneous, as a pathologist will not have the possibility to investigate all cells in all resected 
lymph nodes. Gene expression of GCC in tissue from lymph nodes has shown a good correlation to 
disease outcome, refining correct staging of stage II patients. The test is available as a commercial test 
manufactured as Previstage [51]. A more precise separation of stage II and III CRCs in high- and low 
risk groups have been obtained using mRNA expression profiles of 18 genes, commercialized as 
ColoPrint, Table 2 [46]. Yet another commercially available test, (OncoType DX), uses mRNA 
expression profile of 12 genes in order to indicate a risk of relapse in stage II patients [48]. Also, 
expression of miR-21 has been shown to be correlated to poor survival and therapeutic outcome in 
stage II and III CRCs [52], as well as being an independent predictor of overall survival in CRC [53].  
Table 2. Details of commercially available tests. 
Test name  Biological material Biomarker(s) 
ColoSure
TM  Methylated DNA in feces  Vimentin 
ColoVantage®  Methylated DNA in plasma  SEPT9 
ColoPrint®  mRNA expression in tumor 
tissue 
MCTP1, LAMA3, CTSC, PYROX D1, EDEM1, 
IL2RB, ZNF697, SLC6A11, IL2RA, CYFIP2, 
PIM3, LIF, PLIN3, HSD3B1, ZBED4, PPARA, 
THNSL2, CA4388O2 
OncoType 
DX® 
mRNA expression in tumor 
tissue 
Ki-67, C-MYC, MYBL2, FAP, BGN, INHBA, 
GADD45B, ATP5E, PGK1, GPX1, UBB, VDAC2 
Previstage
TM  mRNA expression in lymph 
node tissue 
GCC (GUCY2C) 
5.4. Predictive Markers 
The  KRAS proto-oncogene is a molecular switch that controls cellular proliferation and 
differentiation, and its activation through EGFR is of essence for its proliferative effect in CRC. Int. J. Mol. Sci. 2011, 12 9433 
 
Overexpression, amplification and mutations of EGFR, resulting in signalling through the MAPK   
and PI3K pathways, are frequent in CRC, and it is therefore a good target for treatment of CRC. For 
metastatic colorectal cancer (mCRC) treatment by EGFR-targeted drugs is one of few therapeutic 
alternatives. However, when EGFRs downstream effector KRAS is mutated, it becomes constitutively 
active, the MAPK pathway is constantly switched on, and thus, treatment targeting EGFR will fail. 
Furthermore, only ~30% of the wild-type KRAS patients benefit from this treatment [69]. This 
indicates that other downstream effectors of the MAPK pathway or the PI3K pathway might have 
activating mutations. There are increasing evidences that the V600E mutation in the BRAF gene also 
inhibits effective treatment with anti-EGFR-therapies [69,70]. Furthermore, mutations in the PIK3CA 
gene, and overexpression of PTEN have also been associated with lack of response, and a combined 
analysis of these four genes would predict outcome in 70% of the patients [71]. Another theory that 
has been suggested for the lack of effect in KRAS wt samples, is heterogeneity within the tumor and 
between primary tumor and metastasis [72,73]. 
A panel of markers has recently been published to be associated with resistance to neoadjuvant 
chemoradiation therapy in rectal cancer [55]. The mutation profile of 23 genes was studied, and 
correlated to patient response to chemoradiation determined, in order to identify which patients will 
benefit from this treatment. Using a subset of four markers (TP53, KRAS, CCND1 and MTHFR), they 
report a specificity of 97%, and a sensitivity of 52% for predicting patients without pathologic complete 
response. This implies a possibility to predict which patients will be resistant to chemoradiation 
therapy, and spare these patients unwanted side-effects [41]. 
Despite the fact that the knowledge of miRNA’s existence is few than 20 years, their function has 
been linked to anticancer chemotherapy in model systems. Resistance to 5-FU and methotrexate has 
been associated with expression of the miRNA miR-140 in the HCT116 cell line [56].  
6. Conclusions and the Way Forward 
Colorectal cancer most frequently develops sporadically, and at an increasing rate also in young 
patients (<50 years), although the highest prevalence still occurs in those aged 60–70 years. As 
patients having a localized disease stage at time of surgery have a very favorable prognosis, the early 
detection of the disease represents a compelling opportunity to reduce the disease burden. Clinical 
symptoms are non-specific, or unnoticeable at early disease stages, therefore there is a need for modes 
of early detection to reduce morbidity and mortality of the disease. Colonoscopy is still the golden 
standard in detecting aberrant lesions, but expensive and unpleasant for the patient. The excitement 
regarding blood and stool-based tests has therefore been great, but to date these tests have shown poor 
sensitivity and specificity compared to colonoscopy. 
Over the last decade, large-scale technology has been implemented in the search for deviations 
underlying diseases. Despite initial optimism regarding the output from these analyses, findings have 
not revolutionized the field of colorectal cancer yet. First and foremost this technology is hypothesis-
generating. Findings must be validated, e.g., with different downstream analysis tools; in new patient 
sample sets; and, with other methods, before robust implementation of biomarkers in the clinic can be 
recommended. The most recent advance in the large-scale technology field is the next-generation 
sequencing methodology. Identification of variants and mutations in an individual tumor will add Int. J. Mol. Sci. 2011, 12 9434 
 
information to the type of cancer and refine classification of the specific tumor. Also, a comparison of 
the whole genome sequence of normal cells from the tumor bearing individual will reveal tumor-specific 
aberrations. In total this can be utilized as prognostic and predictive tools in a clinical setting, and as 
information supporting a more personalized treatment. However, as knowledge about additional 
mechanisms of impairing cell signaling, such as molecular modification of DNA (e.g., methylation), 
regulation of mRNA and protein generation (e.g., miRNA), redundant pathways and genetic mechanisms 
has emerged, the realization that mutation screening solely will probably not reveal outcome of disease 
and treatment has also dawned.  
Several genes and pathways affected by changes have been identified in colorectal tumors, and the 
knowledge about initiation and progression of the disease is extensive. Also, the number of published 
articles aiming at using this knowledge as biomarkers is numerous. However, the implementation of 
this knowledge into clinical practice is so far limited. To date, testing the gene KRAS for activating 
mutations is in routine clinical use, as it has been shown to have predictive information in relation to 
treatment with antibodies against the EGFR-receptor. Findings reported in the literature support 
additional testing of BRAF, PTEN and PIK3CA before anti-EGFR treatment in metastatic colorectal 
cancer. On the other hand, there is an increasing panel of treatments that have been designed to target 
specific genes and pathways, which further highlights the role of normally functioning genes in order 
for the drug to have the desired effect in the patient. 
As more biomarkers are identified and validated it is anticipated that these will be used more 
extensively in clinical decision making. Optimization of tools to predict the risk for developing cancer, 
diagnose a disease at an early stage, give a prognosis that is as correct as possible, and predict 
treatment response in the patient, is of invaluable significance. First and foremost this applies to the 
patient itself, but also to the health personnel, and in a socioeconomic perspective. 
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